Table 5 Comparison between hematological and non-hematological patients with CAPA
|  | Hematologic patients with CAPA n = 20 | Non hematologic patients with CAPA n = 35 | p-value |
|---|---|---|---|
Age, median (IQR), years | 73.5 (66.5–81.75) | 78 (71–85) | 0.23 |
Sex (M), n (%) | 15 (75) | 26 (74.3) |  > 0.99 |
Demographics | |||
 Diabetes, n (%) | 2 (10) | 14 (40) | 0.03 |
 Cardiovascular diseases, n (%) | 4 (20) | 19 (54.3) | 0.02 |
 Hypertension, n (%) | 12 (60) | 28 (80) | 0.13 |
 Chronic respiratory failure, n (%) | 2 (10) | 7 (20) | 0.46 |
 Pulmonary fibrosis, n (%) | 2 (10) | 2 (5.7) | 0.61 |
 Asthma n (%) | 0 (0) | 1 (2.8) |  > 0.99 |
 COPD, n (%) | 6 (30) | 15 (42.8) | 0.40 |
 Bronchiectasis, n (%) | 2 (10) | 3 (8.6) |  > 0.99 |
 Chronic hepatopathy, n (%) | 0 (0) | 0(0) |  > 0.99 |
 Chronic kidney disease, n (%) | 1 (5) | 14 (40) | 0.005 |
 Renal replacement, n (%) | 1 (5) | 3 (8.6) |  > 0.99 |
 Obesity (BMI > 30), n (%) | 2 (10) | 7 (20) | 0.46 |
 Autoimmune disease, n (%) | 0 (0) | 2 (5.7) | 0.53 |
 Immunodeficiency, n (%) | 13 (65) | 5 (14.3) | 0.0002 |
 Hematopoietic stem cells transplant, n (%) | 0 (0) | 0 (0) |  > 0.99 |
 Solid organ transplant, n (%) | 0 (0) | 2 (5.7) | 0.53 |
 CCI, median (IQR) | 5 (4.25–7.75) | 6 (5–9) | 0.22 |
 Apache II, median (IQR) | 12 (9–14.75) | 13 (10–19) | 0.35 |
 Prior (30-d) infections, n (%) | 1 (5) | 8 (22.8) | 0.13 |
 Prior (30-d) chemotherapy, n (%) | 15 (75) | 1 (2.9) |  < 0.0001 |
 Prior (30-d) antibiotic therapy, n (%) | 8 (40) | 12 (34.3) | 0.77 |
 Chronic steroid treatment, n (%) | 8 (40) | 10 (28.6) | 0.55 |
 Anti-CD20 therapy, n (%) | 8 (40) | 1 (2.9) | 0.0007 |
 Lymphocytopeniaa at admission, n (%) | 15 (75) | 25 (71.4) |  > 0.99 |
 Lymphocytic count, median (IQR) | 500 (285–825) | 660 (490–850) | 0.17 |
 Severe or critical COVID-19b | 17 (85) | 31 (88.6) | 0.70 |
 PaO2/FiO2 ratio at admission, median (IQR) | 288.5 (217–336.5) | 201 (143–300) | 0.10 |
 paO2 at admission, median (IQR) | 97.5 (76.25–106) | 74 (66–99) | 0.66 |
 FiO2 at admission, median (IQR) | 35 (22.75–47.5) | 50 (21–60) | 0.31 |
 Length of in-hospital stay, median (IQR), days | 29.5 (22.25–47.75) | 33 (18–58) | 0.91 |
 Transfer to ICU for need for IMV, n (%) | 3 (15) | 3 (8.6) | 0.66 |
 Mortality, n (%) | 13 (65) | 21 (60) | 0.78 |
Respiratory failure treatment at admission | |||
 HFNC, n (%) | 2 (10) | 4 (11.4) |  > 0.99 |
 Venturi mask, n (%) | 14 (70) | 22 (62.9) | 0.77 |
 Helmet CPAP, n (%) | 0 (0) | 3 (8.6) | 0.29 |
 NIV, n (%) | 1 (5) | 3 (8.6) |  > 0.99 |
COVID-19 therapy | |||
 Remdesivir, n (%) | 17 (85) | 18 (51.4) | 0.02 |
 Anti-IL6, n (%) | 10 (50) | 5 (14.3) | 0.01 |
 Monoclonal antibody, n (%) | 3 (15) | 2 (5.7) | 0.34 |